Services Task Force and the American College of Physicians Clinical Guidelines Committee.
METHODS
We followed a protocol developed with stakeholder input. The Appendix Figure (available at www.annals.org) shows the analytic framework and key questions we used to guide this review. The full technical report, which incorporated peer review and public comments, is available on the Agency for Healthcare Research and Quality (AHRQ) Web site (5) .
Data Sources
We searched MEDLINE to identify randomized, controlled trials (RCTs) published from 1985 to 25 November 2011. We manually reviewed reference lists of relevant articles and articles suggested by experts. For complete search strategies, see Appendix 1 (available at www.annals.org).
Study Selection
We applied separate eligibility criteria for CKD screening, monitoring, and treatment (Appendix 2, available at www.annals.org). Trained reviewers examined titles, abstracts, and full articles for eligibility. A second reviewer evaluated a 10% sample of abstracts. When discrepancies were identified, all abstracts initially reviewed by 1 reviewer were reviewed by a second reviewer. Randomized, controlled trials that included participants who at least approximated the definitions for CKD stages 1 to 3 were considered to be eligible for the questions about CKD monitoring and treatment. Only English-language studies were included.
Data Extraction and Quality Assessment
For each article, a first reviewer extracted details on study design, participant characteristics, outcomes, and adverse events and rated study quality. A second reviewer checked the extracted data for accuracy. A priori, we selected mortality and ESRD as our primary efficacy outcomes, followed by clinical cardiovascular events (for example, myocardial infarction [MI] , stroke, and congestive heart failure [CHF]), and composite vascular and renal outcomes that included these outcomes. Biochemical outcomes, such as halving of GFR, doubling of serum creatinine, and conversion from microalbuminuria to macroalbuminuria, were considered secondary and are reported in Supplements 1, 2, and 3 (available at www.annals.org). By using criteria developed by the Cochrane Collaboration (6), we rated individual RCT quality as good, fair, or poor on the basis of the adequacy of allocation concealment (7) , blinding, reporting of reasons for attrition, and how analyses accounted for incomplete data. By using methods developed by the AHRQ and the Effective Health Care Program (8), we evaluated overall strength of evidence for mortality and ESRD outcomes for each treatment comparison on the basis of the criteria of risk for bias, consistency, directness, and precision (Appendix Table 1 , available at www.annals.org). We resolved discrepancies in quality and strength of evidence ratings by discussion and consensus.
Data Synthesis and Analysis
We pooled results if clinical heterogeneity of patient populations, interventions, and outcomes was minimal. Data were analyzed in Review Manager 5.0 (Cochrane Collaboration, Oxford, United Kingdom). Random-effects models were used to generate pooled estimates of relative risks (RRs) and 95% CI. Statistical heterogeneity was summarized by using the I 2 statistic (9) . When there were few RCTs for a given treatment and no overlap of reported outcomes, we synthesized the data qualitatively.
Role of the Funding Source
This review was funded by the AHRQ, and the American College of Physicians Clinical Guidelines Committee provided support for manuscript preparation. Staff at the AHRQ and a technical expert panel, including members of the American College of Physicians Clinical Guidelines Committee and U.S. Preventive Services Task Force and others, helped to develop and refine the scope, and assisted with review of draft manuscripts. The AHRQ granted copyright assertion before the manuscript could be submitted for publication, although the authors are solely responsible for the content and decision to submit it for publication.
RESULTS
Our literature search for RCTs of CKD screening yielded 335 references; 321 were excluded after review of the title and abstract, and the remainder were excluded after review of the full text. Our search for RCTs of monitoring of CKD stages 1 to 3 yielded 920 references, with 901 excluded after review of the title and abstract, and the remainder excluded after review of the full text. Our MEDLINE search for RCTs of treatment of CKD stages 1 to 3 yielded 5291 references, with 4187 excluded after review of the title and abstract and 1012 excluded after review of the full text, leaving 92 eligible trials. Eighteen Figure 2) .
In asymptomatic adults, what evidence is there that systematic CKD screening improves clinical outcomes or is associated with harms?
We found no RCTs of CKD screening in adults who were asymptomatic with or without recognized risk factors for CKD incidence, progression, or complications.
In adults with CKD stages 1 to 3, what evidence is there that systematic monitoring for worsening kidney function and/or kidney damage improves clinical outcomes or is associated with harms?
We found no RCTs of monitoring adults with CKD stages 1 to 3 for worsening kidney function or damage.
Among adults with CKD stages 1 to 3, what evidence is there that treatment improves clinical outcomes?
See the Table for a summary of our findings. ACE Inhibitors. Nineteen eligible RCTs randomly assigned patients with CKD to treatment with ACE inhibitors versus placebo (10 -29) or no treatment (30) . Nearly all trials defined CKD on the basis of albuminuria (10 -25) , including 1 subgroup analysis from a larger trial (16, 30) . Three studies were subgroup analyses of patients with impaired estimated GFR from larger trials (20, 26, 27) .
We found moderate-strength evidence that patients with CKD stages 1 to 3 who were assigned to treatment with an ACE inhibitor had no reduced risk for mortality versus placebo or no treatment (RR, 0.91 [CI, 0.79 to 1.05]; 18 trials) (10 -24, 26, 27, 29) . Although mortality was reduced in RCTs comprising participants with microalbuminuria (RR, 0.79 [CI, 0.66 to 0.96]; 10 trials) (10, 12-14, 16, 18, 19, 21, 24, 29) , these results were driven by 1 trial comprising patients with CVD or highrisk diabetes that included 97% of the deaths in the microalbuminuria subgroup (83). However, in that trial, there was no apparent difference in treatment effect between participants with microalbuminuria (RR, 0. (20, 24, 26, 27) , including 3 subgroup analyses (20, 26, 27) .
We found moderate-strength evidence that ACE inhibitors reduced risk for ESRD versus placebo in patients with CKD stages 1 to 3 (RR, 0.65 [CI, 0.49 to 0.88]; 7 trials) (12, 15-17, 22-24, 30) although this benefit seemed to be driven by 3 trials limited to participants with macroalbuminuria, most of whom also had diabetes and hypertension (RR, 0.60 [CI, 0.43 to 0.83]) (15, 22, 23) . In contrast, risk for ESRD was not statistically significantly reduced in trials comprising persons with CKD defined by microalbuminuria or impaired GFR only, in whom few ESRD events occurred (P ϭ 0.48 for interaction with trials limited to participants with macroalbuminuria). Although patients with CKD stages 1 to 3 assigned to treatment with ACE inhibitors versus placebo had no statistically significant reduction in risk for MI, stroke, or other vascular outcomes and results were mixed for composite vascular outcomes, all 3 trials reporting composite renal outcomes found a reduced risk for this outcome (15, 22, 24) .
Angiotensin II-Receptor Blockers. Among 5 eligible RCTs that compared angiotensin II-receptor blockers (ARBs) with placebo (31-35), we found high-strength evidence that patients with CKD stages 1 to 3 assigned to treatment with ARBs had no reduced risk for mortality (RR, 1.04 [CI, 0.92 to 1.18]; 4 trials) (31) (32) (33) 35) . Results seemed to be similar in subgroups with or without albuminuria (P ϭ 0.26 for interaction). We also found highstrength evidence that ARBs reduced risk for ESRD in patients with CKD stages 1 to 3 (RR, 0.77 [CI, 0.66 to (35, 36, 43) , we found moderatestrength evidence that there was no statistically significant difference in risk for mortality (35-37, 42, 43) and lowstrength evidence that there was no statistically significant difference in risk for ESRD (35, 36, 44) . In 1 trial, combination therapy increased risk for the single reported composite renal outcome versus ACE inhibitors overall, with no significant difference in treatment effect between subgroups of patients with and without reduced estimated GFR or albuminuria (P Ն 0.27 for interaction by CKD status) (35, 36) . In a second trial, combination therapy versus ACE inhibitors reduced risk for 1 reported composite vascular outcome, although treatment benefit was similar in subgroups with and without CKD (P ϭ 0.23 for interaction) (43) .
␤-Blockers. Five eligible RCTs randomly assigned patients with CHF to treatment with ␤-blockers versus placebo and reported subgroup results in participants with impaired estimated GFR (Castagno D, McMurray J. Personal communication) (45) (46) (47) (48) . Nearly all patients were receiving an ACE inhibitor or ARB at baseline. We found moderate-strength evidence that patients with CKD stages 1 to 3 assigned to treatment with ␤-blockers had a reduced risk for all-cause mortality (RR, 0. 73 Thiazide Diuretics. One eligible trial randomly assigned patients with systolic hypertension to treatment with thiazide diuretics versus placebo and reported subgroup results in participants with serum creatinine levels of 119.34 mol/L or greater (Ն1.35 mg/dL) (49). We found low-strength evidence that patients with increased creatinine levels assigned to treatment with thiazide diuretics had no reduction in mortality (RR, 1.17 [CI, 0.74 to 1.85]). However, the thiazide diuretic group had a reduced risk for stroke (RR, 0.49 [CI, 0.24 to 0.99]) and for 1 of 2 reported composite vascular outcomes. In results reported only for 1 composite vascular outcome, the RR between thiazide diuretic and placebo groups did not differ between subgroups with and without increased creatinine (P ϭ 0.96 for trend). No renal outcomes were reported.
Strict Versus Standard Blood Pressure Control. In 7 eligible trials (50 -57), 6 comprised entirely (50 -52, 56) or mostly (54, 55, 57) of patients with hypertension, study participants with CKD stages 1 to 3 were randomly assigned to different targets for treatment of blood pressure. Targets and medications that were used varied among trials, but the strict control target was usually approximately 10 to 15 mm Hg less than the standard control target. In trials reporting follow-up systolic and diastolic blood pressure results, mean achieved blood pressure ranged from 128 to 133 mm Hg for systolic blood pressure and 75 to 81 mm Hg for diastolic blood pressure in the strict control group versus 134 to 141 mm Hg for systolic blood pressure and 81 to 87 mm Hg for diastolic blood pressure in the standard control group (50, 51, 53, 54). The difference in (65, 68) . In addition, patients with CKD stages 1 to 3 assigned to treatment with statins had reduced risk for MI, stroke, and most reported composite vascular outcomes. However, trials consistently found no statistically significant interaction of CKD on treatment group effect for any of these clinical outcomes (59, 60, 62, 64, 67, 69) .
Low-Protein Diet. Six eligible trials randomly assigned patients with CKD stages 1 to 3 to variably defined lowprotein diets versus usual diets (57, 70 -74) . All but 1 study (70) reported results for patients with CKD stages 1 to 3 in combination with those for participants with CKD stages 4 or 5. We found low-strength evidence that low- Mortality: low ESRD: low ACE ϭ angiotensin-converting enzyme; ARB ϭ angiotensin II-receptor blocker; CHF ϭ congestive heart failure; CKD ϭ chronic kidney disease; ESRD ϭ end-stage renal disease; GFR ϭ glomerular filtration rate; MI ϭ myocardial infarction; RCT ϭ randomized, controlled trial; RR ϭ relative risk. * For many treatment comparisons, not all trials reported results for all outcomes. † Strength of evidence was rated using the following grades: 1) High confidence indicated that further research is very unlikely to change the confidence in the estimate of effect, meaning that the evidence reflects the true effect; 2) moderate confidence denoted that further research may change our confidence in the estimate of effect and may change the estimate; 3) low confidence indicated that further research is very likely to have an important impact on the confidence in the estimate of effect and is likely to change the estimate, meaning that there is low confidence that the evidence reflects the true effect; and 4) insufficient, indicating that the evidence was unavailable or did not permit a conclusion. ‡ Included 1 RCT that assigned participants to ACE inhibitor plus ARB vs. ACE inhibitor vs. ARB but reported results only for ACE inhibitor plus ARB vs. the combined monotherapy treatment groups. § Strength of evidence for ACE inhibitor plus ARB vs. ACE inhibitor and strength of evidence for ACE inhibitor plus ARB vs. ARB both took into account results from 1 RCT that assigned participants to treatment with an ACE inhibitor plus ARB vs. ACE inhibitor vs. ARB, but that only reported results for ACE inhibitor plus ARB vs. the combined monotherapy treatment groups.
Review
Screening for, Monitoring, and 
Among adults with CKD stages 1 to 3, what evidence is there that treatment is associated with harms?
Few RCTs reported information on study withdrawals. When withdrawals were reported, they were often high and infrequently were reported separately by treatment group. Few trials reported adverse events, and these often seemed to be neither predefined nor systematically collected or reported. Adverse events reported were consistent with those reported in RCTs not limited to patients with CKD, with risk relative to placebo significantly increased for cough with ACE inhibitors, hyperkalemia with ARBs, and hypotension with ␤-blockers. In 1 large RCT that compared an ACE inhibitor plus ARB combination with an ACE inhibitor alone, combination treatment was associated with a significant increase in risk for cough, hyperkalemia, hypotension, and acute kidney failure requiring dialysis (RR, 1.95 [CI, 1.09 to 3.49]) (35) .
DISCUSSION
We found no RCTs of CKD screening or monitoring and, thus, no direct evidence about their benefits or harms. In contrast, we found direct RCT evidence about the benefits of several treatments for patients with CKD stages 1 to 3, including ACE inhibitors, ARBs, ␤-blockers, and statins. Although CKD increased the absolute risk for adverse clinical vascular and renal events, other than the significantly reduced risk for ESRD with ACE inhibitors or ARBs in patients with macroalbuminuria (most of whom also had diabetes and hypertension), we found little evidence that any relative improvement in clinical outcomes with these treatments versus placebo differed between patients with CKD and those without.
The strongest evidence about the benefits and harms of systematic CKD screening versus usual care or no screening would come from RCTs that report clinical outcomes. We found no such trials. However, other studies have provided indirect evidence about these questions. Clinical and administrative data, primarily from large representative U.S. cohorts, suggest that targeted screening could identify many patients with undiagnosed CKD. First, CKD stages 1 to 3 are common in older patients (2) and in adults with specific illnesses (for example, diabetes, hypertension, and CVD) (84) . Second, most persons with CKD stages 1 to 3, even those with diabetes and hypertension, are not clinically recognized (85) and do not have CKD testing in usual care (86, 87), with albuminuria measured less often than serum creatinine. Albuminuria and serum creatinine-derived estimated GFR are widely available in primary care settings, with high sensitivity and specificity for 1-time measures of renal damage or dysfunction (2). However, the risk for false-positive screening is substantial (88, 89) , and these measures have unknown sensitivity and specificity for CKD as defined by persistently decreased GFR or albuminuria (90) . Further, evidence from CKD treatment trials seems to differ on the basis of whether study participants have macroalbuminuria, microalbuminuria, or impaired estimated GFR, and different CKD screening tests may detect only modestly overlapping groups of patients. Thus, considerations about the potential benefit of CKD screening must be specific to the screening regimen. In that context, modeling studies have incorporated data (including CKD epidemiology, screening test characteristics, and benefits and harms of treatment) to estimate the cost-effectiveness of screening for microalbuminuria (91) or macroalbuminuria (92) . These studies have concluded that, compared with usual care, targeting screening for albuminuria in older patients with diabetes or hypertension and treating patients who screen positive with ACE inhibitors or ARBs may be costeffective. However, these modeling studies may overgeneralize CKD screening benefits. They assume that reductions in mortality risk with ACE inhibitors versus placebo reported in 1 subgroup analysis comprising patients with CKD who have albuminuria and either CVD or high-risk diabetes (16) apply to all patients with albuminuria (for example, including persons with diabetes with no other cardiovascular risk factors and patients with isolated hypertension) (91, 92) . Our review did not find evidence to support this assumption.
The strongest evidence about the benefits and harms of systematic monitoring of patients with CKD stages 1 to 3 for worsening renal function or damage versus usual care or no monitoring would come from RCTs that reported clinical outcomes. We found no such trials. However, data from observational studies suggest that targeted CKD monitoring could identify many patients with unrecognized progression who are at increased risk for adverse clinical outcomes. First, several studies have reported that patients with diabetes, hypertension, hyperlipidemia, obesity, smoking, or proteinuria are more likely to have faster progression of kidney damage or dysfunction (93) (94) (95) . Second, although nearly all patients with diagnosed CKD stages 1 to 3 have serum creatinine levels measured regularly in usual practice, only 30% to 40% are tested annually for albuminuria (86); as a result, albuminuria progression may be unrecognized in many patients. Third, although we are unaware of studies that report the sensitivity and specificity of estimated GFR or albuminuria for identifying persistent progression of CKD stages 1 to 3, and the risk for false-positive identification of CKD progression is unknown, categorically worsening albuminuria in patients with CKD significantly increases risk for mortality and adverse clinical vascular and renal outcomes independent of baseline albuminuria severity (96). Even ac-counting for RCT evidence that selected treatments improve important clinical outcomes in patients with CKD stages 1 to 3, it is uncertain from all this fragmentary evidence whether modifying treatment of worsened CKD detected by monitoring improves clinical outcomes compared with modifying treatment of worsened CKD detected by usual care. Further, we found no modeling studies that quantitatively estimated the effectiveness of any strategy for monitoring progression of CKD stages 1 to 3 followed by treatment of patients with progression versus a control strategy.
We found no RCTs or prospective observational studies of CKD screening or monitoring that reported harms. However, this does not exclude the possibility of harms associated with these interventions. Potential harms of CKD screening are adverse effects from screening and follow-up tests, including follow-up of false-positive results, psychological effects from labeling asymptomatic individuals as having the disease, medication adverse effects, increased medical visits, and increased health care costs. Potential harms of systematic monitoring of patients with CKD stages 1 to 3 for worsening kidney function or damage are adverse effects from monitoring and follow-up tests, including potentially unnecessary testing, medication adverse effects, and increased medical visits and health care costs.
The strongest RCT evidence of the benefit of treating CKD stages 1 to 3 was reduction in risk for ESRD with ACE inhibitors or ARBs. However, this benefit seemed to be limited to the subgroup of patients with CKD who have macroalbuminuria, most of whom had concomitant diabetes and hypertension. Although we found no evidence that ACE inhibitors or ARBs reduced risk for ESRD versus placebo in patients with microalbuminuria or impaired estimated GFR only, ESRD events were rare in these subgroups, and analyses of these studies had low statistical power to detect a treatment-related difference in risk for progression to ESRD. Whether our finding that ACE inhibitors reduced risk for mortality versus placebo when ARBs did not indicates a true advantage of ACE inhibitors over ARBs in patients with CKD stages 1 to 3 is uncertain. The higher prevalence of CVD in trials that compared ACE inhibitors with placebo than in those that compared ARBs with placebo may contribute to this finding. Unfortunately, the 5 RCTs in patients with CKD stages 1 to 3 that compared ACE inhibitors with ARBs and reported clinical outcomes had little power to identify a difference in risk for mortality or any vascular or renal outcome. Among patients with CKD stages 1 to 3, the relative reduction in risk for mortality and other clinical vascular and renal outcomes associated with treatment with ACE inhibitors, ARBs, ␤-blockers, thiazide diuretics, and statins seemed to be limited to patients with specific comorbid conditions and did not differ substantially from that found in patients without CKD. This finding suggests that populations evaluated in these trials may have a clinical indication for such treatments (for example, ACE inhibitors in patients with CVD or high-risk diabetes, ␤-blockers with CHF, and statins with hyperlipidemia), regardless of having CKD or CKD progression.
Additional trials that randomly assigned participants with CKD stages 1 to 3 to more versus less intensive treatment showed no consistent difference in clinical outcomes between treatment groups. Interpretation of trials that compared strict versus standard blood pressure control is complicated by variability in baseline, target, and achieved blood pressures between trials. Similarly, interpretation of trials that compared low-protein with usual diets is complicated by variability in the level of protein prescribed and inclusion of participants with CKD stages 4 to 5 in addition to those with CKD stages 1 to 3. Although neither intensive intervention seemed to reduce the risk for any clinical outcome versus control therapy, given limitations in individual study quality and the few clinical events reported in these trials, future studies are likely to refine these estimates of effect. By comparison, trials that compared ACE inhibitors combined with ARBs versus ACE inhibitors or ARBs alone showed a possibly unfavorable tradeoff between improvement in 1 composite vascular outcome at the cost of increased risk for renal adverse effects, including acute kidney failure requiring dialysis.
This review is limited in part by the available literature, including our inability to identify RCTs that directly evaluated the benefits or harms of CKD screening or monitoring. Inconsistent definitions of CKD and clinical outcomes among treatment trials may limit generalizability of findings across studies. Many RCTs reported few clinical outcomes and even fewer adverse events, limiting our confidence around risk estimates for these outcomes. Because nearly all eligible trials that reported baseline GFR had a mean estimated GFR of 45 mL/min per 1.73 m 2 or greater, results of this review may not apply equally to patients with lower estimated GFRs. Further, many studies were post hoc analyses of subgroups with CKD drawn from RCTs that enrolled more general populations, and many other trials involving the same populations and interventions have not reported results for their subgroups with CKD stages 1 to 3; thus, results of this review may be affected by publication bias. Although the scant attention we paid to biochemical CKD treatment outcomes, such as change in estimated GFR and albuminuria, may also be considered a limitation, our decision to focus the review on clinical outcomes was made a priori. Although these biochemistries are adverse prognostic markers, some trials have reported increases in fatal cardiovascular events (97) and in renal failure requiring dialysis (35) , despite improved albuminuria.
Overall, we found no direct evidence about the benefits or harms of screening patients for CKD or for monitoring patients with CKD stages 1 to 3 for CKD progression. Indirect evidence suggested that targeting CKD screening or monitoring may be possible but that the po-tential benefit of these interventions was uncertain. Evidence for CKD treatment benefit was strongest for ACE inhibitors and ARBs, particularly for reduction in risk for ESRD in patients with macroalbuminuria who also have diabetes and hypertension. Future studies should compare CKD screening and monitoring with usual care on important clinical outcomes. Refined modeling studies of CKD screening and monitoring are warranted. Large-scale treatment RCTs should define CKD according to current criteria. Trials should also be designed a priori to do longterm collection of clinical vascular and renal outcomes and to report outcomes by CKD stage, albuminuria, estimated GFR categories and subcategories (that is, dividing patients with CKD stage 3 into those with estimated GFR Ͻ45 and Ն45 mL/min per 1.73 m 2 ), and important patient characteristics. Judicious use of administrative data sets may also be informative.
APPENDIX 1: LITERATURE SEARCH STRATEGIES
We developed separate search strategies for the screening, monitoring, and treatment key questions. We searched MEDLINE and developed and tested search strings to identify RCTs or controlled clinical trials. We included studies that enrolled an adult population (aged Ն18 years), were published since 1985, and were written in English. Evidence suggests that for systematic reviews of conventional medicine, which were evaluated in the present review, restriction to include only English-language trials should not bias estimates of the effectiveness of the interventions. Only full articles were included. Details of the major search strategies are provided in Appendix Table 2 .
To identify systematic reviews related to the 3 topic areas, we completed a search of MEDLINE using the same search strategies as detailed in Appendix Table 2 , with the addition of publication-type terms to identify systematic reviews. We manually searched the reference lists of the identified systematic reviews to identify any RCTs or controlled clinical trials that were not identified in our electronic literature search. We also manually searched reference lists of the primary reports that were eligible for inclusion in the review. Per project protocol, because we did not find evidence from RCTs or controlled clinical trials to directly address whether screening or monitoring impact clinical outcomes or harms, we conducted a nonsystematic search for observational studies to identify indirect evidence about the benefits and harms of screening for and monitoring of CKD. All citations were then imported into EndNote X (Thomson Reuters, New York, New York) and Excel (Microsoft, Redmond, Washington) for abstract review and database management.
A broad search of the gray literature was completed by the AHRQ Scientific Resource Center librarian. Gray literature, which, by definition, is not systematically stored or indexed, included abstracts presented at conferences, unpublished trial data, government documents, and scientific information packets from pharmaceutical companies on medications evaluated in this topic.
We conducted the initial searches in March and April 2010. All searches were updated in January 2011 and again in November 2011.
APPENDIX 2: TRIAL ELIGIBILITY CRITERIA
We developed criteria for inclusion and exclusion of studies based on patient populations, interventions, outcome measures, and types of evidence relevant to the key questions. Within the sections for each pair of key questions, inclusion criteria are detailed in the Patients sections and exclusion criteria are detailed in the Study Selection sections.
Key Questions 1 and 2: Benefits and Harms of CKD Screening Patients
We restricted the review to studies that enrolled adults without known CKD, who did or did not have recognized risk factors for CKD, and who were systematically screened for CKD. Because much of our search period preceded the development and wide implementation of the current CKD staging system, studies whose definitions of CKD at least closely approximated the current Kidney Disease Outcomes Quality Initiative and Kidney Disease: Improving Global Outcomes definitions for CKD stages 1 to 3 were considered eligible.
Study Selection
We sought RCTs or controlled clinical trials that assessed the direct effect of systematic screening for CKD stages 1 to 3 on clinical outcomes and harms. Examples of tests to screen for CKD that were considered eligible were direct measurements of GFR or creatinine clearance, estimation of GFR or creatinine clearance with creatinine-based formulae, serum creatinine, albuminuria, proteinuria, albumin-creatinine ratio, and cystatin C. The screening method must have been feasible within a primary care setting. Our exclusion criteria were as follows: nonadult population, study participants already diagnosed with CKD, not an RCT that assigned participants to have systematic screening for CKD versus usual care or a comparator intervention, study follow-up duration less than 1 year, and sample size less than 1000 randomly assigned participants.
When no RCTs were identified that evaluated a CKD screening intervention and reported clinical outcomes and harms, indirect evidence was reviewed about its possible benefits and harms. This indirect evidence included observational studies on CKD prevalence, clinical recognition, accuracy and reliability of CKD screening tests, and RCTs of CKD treatments. Although these observational studies were not identified by a comprehensive literature search, whenever possible, we evaluated data from large representative U.S. cohorts. Assessment of CKD treatment benefits and harms was based strictly on direct evidence from RCTs.
Comparators
Studies compared systematic screening for CKD stages 1 to 3 with no CKD screening, usual care, or an alternative CKD screening regimen. Any monitoring or treatment interventions that followed screening were allowed.
Outcomes
We restricted the review to studies that reported clinical outcomes or harms. Clinical outcomes were all-cause mortality, cardiovascular mortality, MI (any, fatal, or nonfatal), stroke (any, fatal, or nonfatal), CHF (hospitalization or death), composite vascular outcomes, composite renal outcomes, ESRD (progression to kidney transplant or dialysis), quality of life, physical function, and activities of daily living. Intermediate outcomes were progression to stage 4 or 5 kidney disease, doubling of serum creatinine or halving of estimated GFR, and conversion from microalbuminuria to macroalbuminuria. Harms were any adverse events, serious adverse events, specific adverse events, and any renal adverse events.
Study Designs
We initially included only RCTs. As described above, when no relevant RCTs were identified, we expanded our search to include observational studies that could provide indirect evidence about these questions.
Key Questions 3 and 4: Benefits and Harms of CKD Monitoring Patients
We restricted the review to studies that enrolled adults with CKD stages 1 to 3 who were systematically monitored for worsening of kidney function or damage. As above, studies whose definitions of CKD stages 1 to 3 at least closely approximated the current Kidney Disease Outcomes Quality Initiative and Kidney Disease: Improving Global Outcomes definitions were considered eligible.
Study Selection
We sought RCTs or controlled clinical trials that assessed the direct effect of monitoring on clinical outcomes and harms. Examples of tests to monitor for worsening kidney function or damage that were considered eligible were direct measurements of GFR or creatinine clearance, estimation of GFR or creatinine clearance with creatinine-based formulae, serum creatinine, albuminuria, proteinuria, albumin-creatinine ratio, and cystatin C. The monitoring method must have been feasible in a primary care setting. Our exclusion criteria were as follows: nonadult population, population entirely or predominately did not have CKD stages 1 to 3, not an RCT that assigned participants to have systematic monitoring for worsening of kidney function or damage versus usual care or comparator interventions, and sample size of fewer than 50 randomly assigned participants.
When no RCTs were identified that evaluated CKD monitoring interventions and reported clinical outcomes or harms, indirect evidence was reviewed about its possible benefits and harms. This indirect evidence included observational studies on CKD progression, clinical recognition, accuracy and reliability of CKD monitoring tests, and RCTs of CKD treatments. Although these observational studies were not identified by a comprehensive literature search, whenever possible, we evaluated data from large representative U.S. cohorts. Assessment of CKD treatment benefits and harms was based strictly on direct evidence from RCTs.
Comparators
Studies compared systematic monitoring of patients with CKD stages 1 to 3 for changes in kidney function or damage with usual care or an alternative CKD monitoring regimen. Any interventions that followed CKD monitoring were allowed.
Outcomes
We restricted the review to studies that reported clinical outcomes or harms. Clinical outcomes were all-cause mortality, cardiovascular mortality, MI (any, fatal, or nonfatal), stroke (any, fatal, or nonfatal), CHF (hospitalization or death), composite vascular outcomes, composite renal outcomes, ESRD (progression to kidney transplant or dialysis), quality of life, physical function, and activities of daily living. Intermediate outcomes were progression to stage 4 or 5 kidney disease, doubling of serum creatinine or halving of GFR, and conversion from microalbuminuria to macroalbuminuria. Harms were any adverse events, serious adverse events, specific adverse events, and any renal adverse events.
Study Designs
We initially included only RCTs. As previously described, when no relevant RCTs were identified, we expanded our search to include observational studies that could provide indirect evidence about these questions.
Key Questions 5 and 6: Benefits and Harms of CKD Treatment Patients
We restricted the review to studies that enrolled adults with CKD stages 1 to 3. Again, studies whose definitions of CKD stages 1 to 3 at least closely approximated the current Kidney Disease Outcomes Quality Initiative and Kidney Disease: Improving Global Outcomes definitions were considered eligible.
Interventions
We included studies of both CKD-specific and nonspecific treatments. We attempted to identify studies of ACE inhibitors, ARBs, calcium-channel blockers, aldosterone antagonists, ␣-blockers, ␤-blockers, loop diuretics, thiazide and related diuretics, combination antihypertensive regimens, targeting thresholds of blood pressure control independent of specific antihypertensive agent or agents, insulin, sulfonylureas, thiazolidinediones, biguanides (for example, metformin), targeting thresholds for glycemic control, statins, bile acid sequestrants, cholesterol absorption inhibitors (for example, ezetimibe), anorexiants, lipase inhibitors, low-protein diets, and other diets.
Comparators
These studies compared active treatment of patients with CKD stages 1 to 3 with placebo, usual care or no treatment, or with other active treatments, including combination treatment, and comparisons with the same active treatments using different dose levels or targeting different treatment thresholds.
Outcomes
Study Designs
We included only RCTs.
Study Selection
Separate literature searches were completed for the 3 main topic areas: screening, monitoring, and treatment. Results of each literature search were imported to a spreadsheet for screening. Trained reviewers examined all titles and abstracts for eligibility based on the inclusion or exclusion criteria for the topic area of the search. Titles and abstracts with insufficient information to determine eligibility were pulled for review of the full-text article. If the initial reviewer was uncertain about eligibility, 1 of the physician project leads reviewed the abstract (or article) and made a final decision about inclusion or exclusion. We selected a 10% sample (representing the work of all abstract reviewers) for repeated review. Because of discrepancies between the results of 1 initial reviewer and the second reviewer, all abstracts reviewed by the initial reviewer were reviewed a second time. Overall, we asked abstract reviewers to err on the side of inclusion rather than exclusion. Reasons for exclusion were tallied in the spreadsheet and entered in an EndNote file for reference list management. We also applied the inclusion or exclusion criteria to studies identified in the hand-search of reference lists and in the review of studies cited in relevant systematic reviews. Additional references suggested by members of our technical expert panel and by the public during the comment period were also reviewed for eligibility.
